Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twice-daily versus titrated insulin glargine (iGlar)on renal function and albuminuria in type 2 diabetes (T2DM)patients. Methods: We post-hoc evaluated renal outcome-data of 54 overweight T2DM patients (mean ± SD age 60 ± 8 years, HbA1c 7.5 ± 0.9%, eGFR 86 ± 16 mL/min/1.73 m2, median [IQR]urinary albumin-to-creatinine-ratio (UACR)0.75 [0.44–1.29]mg/mmol)randomised to exenatide 10 µg twice-daily or titrated iGlar on-top-of metformin for 52-weeks. Renal efficacy endpoints were change in creatinine clearance (CrCl)and albuminuria (urinary albumin-excretion [UAE]and UACR)based on 24-h urines, collected at baseline and Week-52. eGFR and exploratory endpoints were coll...
OBJECTIVE A post hoc analysis to investigate the association between 1-year changes in albuminuria a...
OBJECTIVE: We aimed to investigate the individual impact of initial responses in urinary albumin exc...
Background: In the AWARD-7 trial of participants with type 2 diabetes (T2DM) and moderate-to-severe ...
Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twicedaily versus tit...
Aims: To evaluate the effects of separate and combined use of the sodium-glucose cotransporter-2 (SG...
The effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in patients wi...
Aims/hypothesis: This study aimed to investigate the acute renal effects of the glucagon-like peptid...
Aims: To examine the albuminuria-lowering effect of exenatide once weekly (EQW) compared with active...
Aims/hypothesis: This study aimed to investigate the acute renal effects of the glucagon-like peptid...
Aim: To determine whether lixisenatide, a prandial short-acting glucagon-like peptide receptor agoni...
AIM: To determine whether lixisenatide, a prandial short-acting glucagon-like peptide receptor agoni...
Background: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA1...
Background: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA1...
OBJECTIVE A post hoc analysis to investigate the association between 1-year changes in albuminuria a...
OBJECTIVE: We aimed to investigate the individual impact of initial responses in urinary albumin exc...
Background: In the AWARD-7 trial of participants with type 2 diabetes (T2DM) and moderate-to-severe ...
Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twicedaily versus tit...
Aims: To evaluate the effects of separate and combined use of the sodium-glucose cotransporter-2 (SG...
The effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in patients wi...
Aims/hypothesis: This study aimed to investigate the acute renal effects of the glucagon-like peptid...
Aims: To examine the albuminuria-lowering effect of exenatide once weekly (EQW) compared with active...
Aims/hypothesis: This study aimed to investigate the acute renal effects of the glucagon-like peptid...
Aim: To determine whether lixisenatide, a prandial short-acting glucagon-like peptide receptor agoni...
AIM: To determine whether lixisenatide, a prandial short-acting glucagon-like peptide receptor agoni...
Background: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA1...
Background: In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide reduced HbA1...
OBJECTIVE A post hoc analysis to investigate the association between 1-year changes in albuminuria a...
OBJECTIVE: We aimed to investigate the individual impact of initial responses in urinary albumin exc...
Background: In the AWARD-7 trial of participants with type 2 diabetes (T2DM) and moderate-to-severe ...